Overview Study of TG-1801 in Subjects With B-Cell Lymphoma Status: Recruiting Trial end date: 2022-12-01 Target enrollment: Participant gender: Summary Phase 1 first in human Study to Assess the Bispecific Antibody TG-1801 in Subjects with B-Cell Lymphoma Phase: Phase 1 Details Lead Sponsor: TG Therapeutics, Inc.